Read about our collaborative study with Amsterdam UMC on a multicellular human 3D Blood-Brain Barrier (BBB) on-a-chip model comprising human brain microvascular endothelial cells (HBMECs). This model provides critical insights into barrier disruption, endothelial inflammation, and T cell migration under neuroinflammatory conditions, mimicking diseases like multiple sclerosis and stroke. The BBB-on-a-chip shows great potential for studying immune cell infiltration and evaluating new therapeutic strategies. Notably, the findings indicate that T cell migration is reduced by Natalizumab, a treatment for multiple sclerosis. This research marks a significant advancement in understanding neuroinflammation and developing targeted therapies for neurological disorders. 🔗 Read the full article here: https://lnkd.in/eqE9KdJW #Neuroscience #Research #BloodBrainBarrier #OrganOnAChip #Neuroinflammation
Over ons
We strive to contribute to groundbreaking therapies with our screenable, physiologically relevant 3D human disease models. By combining technological strengths and expertise, we establish strong drug development partnerships with and offer services to global pharmaceutical companies to develop innovative therapies to target untreatable diseases. For more information, visit: www.mimetas.com.
- Website
-
https://mimetas.com
Externe link voor MIMETAS
- Branche
- Biotechnologisch onderzoek
- Bedrijfsgrootte
- 51 - 200 medewerkers
- Hoofdkantoor
- Oegstgeest
- Type
- Particuliere onderneming
- Opgericht
- 2013
- Specialismen
- organ-on-a-chip, microfluidics, 3D cell culture, cell-based assays, toxicology, tissue models, disease models, microphysiological systems, MPS, organoids, blood-brain barrier, liver, brain models, liver models, kidney models, 3D, disease modeling, phenotypic screening en high-throughput
Locaties
-
Primair
De Limes 7
Oegstgeest, 2342DH, NL
-
704 Quince Orchard Road
Suite 260
Gaithersburg, Maryland 20878, US
-
1-8-2 Marunouchi, Chiyoda-ku
4F
Tokyo, Tokyo 100-0005, JP
Medewerkers van MIMETAS
Updates
-
MIMETAS heeft dit gerepost
💻 ON-DEMAND WEBINAR: Advancing Toxicity Research with 3D Tissue Models and Novel Imaging Techniqes In case you missed it, or would just like to re-watch the webinar, we teamed up with experts from MIMETAS to discuss how pre-clinical in vitro toxicity evaluation of drug compounds can draw meaningful conclusions about safety studies for drug discovery. We also share insights from three comprehensive and reproducible #3DTissueModels and their toxic responses to drug and inflammatory mediators using various types of assays. Key takeaways include: — Discover how to scale up high-throughput workflows by leveraging the #OrganoPlate platform's compatibility with high-content imaging — Understand how #LabAutomation can increase the efficiency and productivity of tedious 3D drug screening workflows — Learn how to create disease-related 3D model workflows for screening and #DrugDiscovery Watch here: https://bit.ly/3SlMSqa #3DBiology #AutomatedWorkflow #HighContentImaging #HighContentScreening
Advancing Toxicity Research with 3D Tissue Models and Novel Imaging Techniques
moleculardevices.com
-
Check out our brand new app note: High-Throughput Toxicity Assessment in OrganoReady® Blood Vessel HUVEC! Snakebites are a major global health issue, affecting millions either fatally or leaving them with permanent injury by disrupting blood vessels. In this app note, we describe an assay to assess vascular toxicity from various snake venoms in the OrganoReady® Blood Vessel HUVEC 3-lane 64 using a multimode microplate reader. 🔬 Key Highlights: - 64 ready-to-use 3D human blood vessels in the OrganoPlate® - Image-based protocols for real-time monitoring of endothelial barrier function, cell viability, and morphological changes - High-throughput assessment of vascular toxicity and inflammation 🔗 Read the app note: https://lnkd.in/eu6xYdSr #SnakebiteResearch #ToxicityAssessment #BiotechInnovation
App Note: High-Throughput Toxicity Assessment in OrganoReady® Blood Vessel HUVEC
mimetas.com
-
We're proud to be contributing to Project SECRET - a consortium focused on exploring the therapeutic potential of perinatal cell SECRETomes!
🚀”SECRET” Receives EU Funding to Launch a MSCA Doctoral Network Focused on Regenerative Medicine 🚀 Exploring the therapeutic potential of perinatal cell SECRETomes – We are thrilled to announce that Project SECRET - coordinated by Prof. Ornella Parolini of Università Cattolica del Sacro Cuore (UCSC), Rome - is an innovative doctoral network under the Horizon Europe programme which has been awarded significant EC funding to propel its groundbreaking research. It will be entirely dedicated to the characterization of perinatal secretomes with regenerative potential for neurological and cardiovascular disorders. This funding will enable the recruitment of 10 talented doctoral candidates in the next months, who will become the driving force behind this pioneering project. Our contributors to SECRET training programme are Università di Genova, Universitaetsklinikum Essen, Universiteit Antwerpen, Universidade do Minho, Academisch Medisch Centrum Bij De Universiteit Van Amsterdam, Università degli Studi “Gabriele D’Annunzio” di Chieti-Pescara, Fondazione Poliambulanza, Ente Ospedaliero Cantonale, Innovation Acta S.r.l., MIMETAS BV. 📣Start date of the project will be 1st September so stay tuned for more updates and insights!
-
Do you want to be the first to hear about our latest 3D tissue models, service/product launches, and new publications and resources? 📩 Our newsletter is your gateway to exclusive insights and developments - delivered directly to you! By subscribing, you'll get: 🔬 The latest research and developments from us and our collaborators 📚 New publications & resources 🛠️ New service & product announcements 📅 Invitations to upcoming webinars and events Stay informed and connected with the most advanced innovations in the field of human 3D tissue disease modeling. Subscribe to our newsletter and never miss an update: https://lnkd.in/eBXdpksJ #Newsletter #3DTissueModels #ScienceandInnovation #Biotech
Newsletter
mimetas.com
-
One of our latest webinars is now available on demand! The webinar, “Modelling ADC- and Chemotherapy-Induced Peripheral Neuropathy-on-a-Chip" features Catherine Rodger, PhD (AstraZeneca) and Xandor Spijkers (MIMETAS). 🔍 Key discussion topics include: - Insights into comprehensive 3D in vitro modeling of nerve damage induced by chemotherapeutics like MTIs. - The utilization of our developed model to better investigate the toxicity of ADCs. - The benefits of partnering with MIMETAS in your drug discovery efforts, aimed at mitigating toxic side-effects and achieving better future treatments. Watch it now: https://lnkd.in/gjStCsb8 #Webinar #DrugDiscovery #PeripheralNeuropathy #ToxicityResearch
Webinar | Modeling ADC- and Chemotherapy-Induced Peripheral Neuropathy-on-a-Chip
mimetas.com
-
We're delighted to announce that MIMETAS has contributed vital human organ-on-chip data to support an Investigational New Drug (IND) application by argenx. This preclinical collaboration investigated the effects of a novel candidate in a human in vitro disease assay in MIMETAS’ OrganoPlate platform. The results contributed to the IND application, representing a significant milestone for both MIMETAS and argenx. This aligns with the 2022 FDA Modernization Act 2.0, emphasizing the importance of advanced in vitro models for drug safety and effectiveness. “By embracing advanced human in vitro models over traditional methods like 2D cell culture and animal models, we can bridge a critical gap towards advancing new therapies,” says our CEO, Jos Joore. 🔗 Read the press release: https://lnkd.in/e-yaPQS6 #DrugDiscovery #InnovativeScience #IND #FDA #Pharma
MIMETAS Contributes with Human Organ-on-Chip Data to IND Application by argenx
mimetas.com
-
Are you looking to elevate your toxicity research? At MIMETAS, we advance your compound profiling and screening through complex, human-relevant assays for high-throughput toxicity assessments. Our 3D human tissue models are developed to provide you with accurate, reliable, and actionable data, supporting the development of more effective therapies. 💡 Swipe through to get inspired by some of our toxicity applications and offerings. Discover how MIMETAS can support your specific preclinical research needs: https://lnkd.in/ewYbgQ5c #ToxicityResearch #CompoundProfiling #HighThroughputScreening #OrganOnAChip
-
MIMETAS heeft dit gerepost
Today marks our last day of the MasterClass in Amsterdam where we get inspired by the amazing technologies of intestine on a chip! Missed this one? Visit our website for the upcoming events: https://lnkd.in/dxFsdWUk Should you use organ on a chip technology and if so how should you approach this? Yesterday we answered these questions through: - Expert views by dr Jianbo Zhang and dr Sebo Withoff were we gain in-depth insights on ongoing intestine on a chip research - Commercial session by MIMETAS and Dynamic42 GmbH where the different technologies are showcased. - Organ on a chip Challenge where you develop your own organ on a chip assay And today we wrap up with the Organ on a chip Challenge presentations where we apply the knowledge to showcase organ on a chip assays that the participants develop from an idea to concrete plans. This always leads to fruitful and lively discussions and sometimes these ideas even go into execution! Follow us to stay up to date with upcoming MasterClasses and more!
-
-
Snapshots from Europe's largest neuroscience congress, Federation of European Neuroscience Societies - FENS Forum 2024, where cutting-edge research and innovation in neuroscience take center stage. Our Director of Biology Services, Nienke Wevers, had the pleasure of presenting our latest breakthroughs to an enthusiastic audience. 📊 We showcased two insightful posters: - "Blood-Brain Barrier On-A-Chip To Study Compound-Induced Disruption" - "Human BBB-On-A-Chip Reveals Barrier Disruption, Endothelial Inflammation, And T Cell Migration Under Neuroinflammatory Conditions" Nienke's presentations sparked engaging discussions on these critical areas of research, highlighting the advancements MIMETAS is making in understanding the complexities of the blood-brain barrier and neuroinflammation. 📥 Interested in diving deeper into our findings? Download our BBB app note here: https://lnkd.in/eReeHJQX #FENS2024 #Neuroscience #Research #BloodBrainBarrier #Neuroinflammation
-